SCHEDULE: Frazier Life Sciences Updates Savara Inc. Stake

Frazier Life Sciences entities and individuals have filed an amended Schedule 13G, detailing their beneficial ownership in Savara Inc. common stock.

Summary

• Frazier Life Sciences Public Fund, L.P. (FLSPF), along with its general partners FHMLSP, L.P. and FHMLSP, L.L.C., collectively beneficially own 8,343,048 shares of Savara Inc. common stock, representing 4.1% of the class.
• Frazier Life Sciences X, L.P. (FLS X), its general partners FHMLS X, L.P. and FHMLS X, L.L.C., and members James N. Topper and Patrick J. Heron, collectively beneficially own 279,365 shares, representing 0.1% of the class.
• Frazier Life Sciences XI, L.P. (FLS XI), along with its general partners FHMLS XI, L.P. and FHMLS XI, L.L.C., collectively beneficially own 1,239,888 shares, representing 0.6% of the class.
• The shares held by FLSPF include those acquired from Frazier Life Sciences Public Overage Fund, L.P. through a merger.
• All percentages are calculated based on 203,467,845 shares of Savara Inc. Common Stock outstanding as of November 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Savara Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive update. While a routine filing, the continued significant, albeit passive, investment by Frazier Life Sciences in Savara Inc. can be interpreted as a vote of confidence in the company's long-term value.

Positives

• Frazier Life Sciences, a prominent investment firm, maintains a significant, albeit passive, stake in Savara Inc., indicating continued interest in the company's long-term prospects.

Negatives

• No specific negative information is disclosed in this Schedule 13G filing, which primarily reports beneficial ownership.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Savara Inc. or the reporting persons regarding the company's future performance.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes. While not indicative of a change in control, the continued presence of a specialized life sciences investor like Frazier Life Sciences in Savara Inc.'s shareholder base suggests ongoing confidence in the biotechnology sector and potentially Savara's specific therapeutic pipeline or market position. This type of filing is routine for large investors to update their holdings.

Related Party Transactions

• Shares held by Frazier Life Sciences Public Fund, L.P. were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between the two entities, indicating an internal restructuring of holdings within the Frazier Life Sciences group.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially reinforcing confidence in the stock due to a reputable investor's continued stake.
• Management: Awareness of a large, passive institutional holder, though without direct control influence.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership by a passive institutional investor and does not contain new material information that would warrant a change in investment recommendation. The continued stake by Frazier Life Sciences is a neutral-to-slightly-positive signal, but without further operational or financial updates from Savara Inc., a 'hold' recommendation is appropriate for seasoned investors.

Keywords

Savara Inc., Frazier Life Sciences, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Biotechnology, Pharmaceuticals